Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 1
2016 4
2017 2
2019 2
2020 2
2021 1
2023 2
2024 2
2025 2
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. Holloway RW, et al. Among authors: crafton sm. Int J Gynecol Cancer. 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. Int J Gynecol Cancer. 2023. PMID: 37666539 Free article. Clinical Trial.
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Haight PJ, et al. Among authors: crafton s. Gynecol Oncol. 2025 Mar;194:98-104. doi: 10.1016/j.ygyno.2025.02.013. Epub 2025 Feb 21. Gynecol Oncol. 2025. PMID: 39985870
MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
Borden LE, Cosgrove CM, Washington CR, Thomas SM, Haight PJ, Brown A, Powell K, Harsono A, Mullen M, Crafton S, Jackson AL, Corr BR, Wright JD, Konecny GE, Bae-Jump VL, Podwika SE, Smitherman C, Maxwell GL, Backes FJ, Pothuri B, Ko EM, Arend RC, Thaker PH, Duska LR, Secord AA, Moore KN. Borden LE, et al. Among authors: crafton s. Gynecol Oncol. 2026 Aug;211:231-237. doi: 10.1016/j.ygyno.2026.07.008. Epub 2026 Jul 17. Gynecol Oncol. 2026. PMID: 42468445
20 results